Phase II study of NAB-paclitaxel in sensitive and refractory relapsed SCLC (NABSTER TRIAL)Francesco Gelsomino, Andrea Ardizzoni, Marcello Tiseo et al.|Annals of Oncology|2018Cited by 2
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).Antonino Musolino, Filippo Montemurro, A. Caldara et al.|Journal of Clinical Oncology|2017Cited by 0